Clinical perspectives of β-carbolines from first studies in humans
- 30 September 1987
- journal article
- clinical trial
- Published by Elsevier in Brain Research Bulletin
- Vol. 19 (3) , 319-326
- https://doi.org/10.1016/0361-9230(87)90100-6
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Amnestic effects of lormetazepam and their reversal by the benzodiazepine antagonist Ro 15-1788Psychopharmacology, 1987
- Human studies on the benzodiazepine receptor antagonist ?-carboline ZK 93 426: preliminary observations on psychotropic activityPsychopharmacology, 1987
- Changes in noradrenaline plasma levels and behavioural responses induced by benzodiazepine agonists with the benzodiazepine antagonist Ro 15-1788Psychopharmacology, 1986
- Actions of the?-carboline ZK 93426 in an animal test of anxiety and the holeboard: Interactions with Ro 15-1788Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1986
- Intrinsic actions of the benzodiazepine receptor antagonist Ro 15-1788Psychopharmacology, 1986
- Biochemical evidence that 2-phenyl-4[2-(4-piperidinyl) ethyl]quinoline, a quinoline derivative with pure anticonflict properties, is a partial agonist of benzodiazepine receptorsNeuropharmacology, 1984
- CGS 9896: A nonbenzodiazepine, nonsedating potential anxiolyticDrug Development Research, 1984
- CGS 8216: Receptor binding characteristics of a potent benzodiazepine antagonistLife Sciences, 1982
- INVESTIGATION IN MAN OF THE EFFICACY OF A BENZODIAZEPINE ANTAGONIST, Ro 15-1788The Lancet, 1981
- A 3 min reasoning test based on grammatical transformationPsychonomic Science, 1968